Erratum: Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer (JAMA Oncology (2015) 1:7 (897-906) DOI: 10.1001/jamaoncol.2015.2316);Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer

JAMA Oncology

Volumn 1, Issue 7, 2015, Pages 897-906

  Kalbasi, Anusha ^a   Li, Jiaqi ^b   Berman, Abigail T ^a   Swisher McClure, Samuel ^a,d   Smaldone, Marc ^c   Uzzo, Robert G ^c   Small, Dylan S ^b   Mitra, Nandita ^b   Bekelman, Justin E ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; FACTUAL DATABASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

COMPARATIVE EFFECTIVENESS RESEARCH; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84965091423     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0281     Document Type: Erratum

References (36)

1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of theMD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(1): 67-74.
2. Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014; 110(1): 104-109.
3. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010; 28 (7): 1106-1111.
4. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011; 80(4): 1056-1063.
5. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014; 15(4): 464-473.
6. Andriole GL, Crawford ED, Grubb RL III, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13): 1310-1319.
7. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13): 1320-1328.
8. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302(11): 1202-1209.
9. Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102(13): 950-958.
10. Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158(10): 709-717.
11. Michalski JM, Moughan J, Purdy JA, et al. Initial results of a phase III randomized study of high-dose 3DCRT/IMRT vs standard-dose 3DCRT/IMRT in patients treated for localized prostate cancer (RTOG 0126). 2014. http: //www.oncolink.org /conferences/article.cfm?id=7098. Accessed June 9, 2015.
12. American College of Surgeons. About the National Cancer Database. https: //www.facs.org /quality-programs/cancer/ncdb/about. Accessed January 25, 2015.
13. American College of Surgeons Commission on Cancer. Participant User Files. http: //ncdbpuf.facs .org/?q=node/321. Accessed January 15, 2015.
14. Swisher-McClure S, Mitra N,Woo K, Smaldone M, Uzzo R, Bekelman JE. Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2014; 89(1): 103-112.
15. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2015. www.nccn.org. Accessed June 15, 2015.
16. Hill AB. The environment and disease: Association or causation? Proc R Soc Med. 1965; 58: 295-300.
17. Kalbasi A, Swisher-McClure S, Mitra N, et al. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer. 2014; 120(19): 3089-3096.
18. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012; 118(17): 4280-4289.
19. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007; 45(10)(suppl 2): S103-S107.
20. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127(8 Pt 2): 757-763.
21. Rubin DB, Thomas N. Matching using estimated propensity scores: Relating theory to practice. Biometrics. 1996; 52(1): 249-264.
22. Collett D. Modelling Survival Data in Medical Data. 2nd ed. New York, NY: Chapman & Hall CRC Texts in Statistical Science; 2003.
23. Mattei A. Estimating and using propensity score in presence of missing background data: An application to assess the impact of childbearing on wellbeing. Stat Methods Appl. 2009; 18: 257-273. doi: 10.1007/s10260-007-0086-0.
24. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer Science & Business Media; 2003.
25. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000; 87(3): 706-710. doi: 10.1093/biomet/87.3.706.
26. Mitra N, Heitjan DF. Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Stat Med. 2007; 26(6): 1398-1414.
27. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998; 54(3): 948-963.
28. Spillman BC. Changes in elderly disability rates and the implications for health care utilization and cost. Milbank Q. 2004; 82(1): 157-194.
29. Cawthon PM, Marshall LM, Michael Y, et al; Osteoporotic Fractures in Men Research Group. Frailty in older men: Prevalence, progression, and relationship with mortality. J AmGeriatr Soc. 2007; 55(8): 1216-1223.
30. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variablemethods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010; 19(6): 537-554.
31. Rassen JA, BrookhartMA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables, I: Instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009; 62(12): 1226-1232.
32. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015; 33(3): 272-277.
33. Spratt DE, Zumsteg ZS, Ghadjar P, et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int. 2014; 114 (3): 360-367.
34. Warde P, Mason M, Ding K, et al; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet. 2011; 378 (9809): 2104-2111.
35. Widmark A, Klepp O, Solberg A, et al; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet. 2009; 373(9660): 301-308.
36. KoshyM, Malik R,Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015; 91(2): 344-350.